The ubiquitous mitogen-activated protein kinase (MAPK) pathway regulates many different biological processes and plays critical roles in multiple diseases including cancer (Kim and Choi, 2015). In Caenorhabditis elegans this pathway also is required for the transition of meiotic cells to progress to oocytes (Lee et al., 2007). Previous work from our lab identified a pachytene exit defect in
dlc-1 mutant worms (Ellenbecker et al., 2019). This observation of a disrupted transition from meiotic cells to differentiate into oocytes prompted the investigation of the potential role of the
dlc-1 within the MAPK signaling pathway. DLC-1 (dynein light chain) is a small protein that can function either dependently or independently of the dynein motor and neither functions are suggested to be associated with the MAPK pathway. We hypothesize that the dynein motor is involved with the MAPK pathway and through its involvement contributes to the normal progression of meiosis to oogenesis. Western blot analysis of
dlc-1 mutant worms revealed that activated MAPK in somatic cells was unaffected but decreased in the germline. In wild type C. elegans germlines, active MAPK is found near the end of the meiotic pachytene and in the oocytes. Since we are interested in the meiotic pachytene, further immunostaining analysis was necessary. Here we report that active MAPK levels in the meiotic pachytene decreased in all treatments that disrupted dynein motor function.
dlc-1 and
dhc-1 (dynein heavy chain) mutants express the decreased active MAPK phenotype 35% and 80% of the time respectively. Additionally, we performed RNA interference (RNAi) on N2 worms and noted an even more drastic decrease in active MAPK expression with different components of the dynein motor.
dnc-1 (dynactin subunit) and
dyci-1 (dynein intermediate chain) RNAi experiments showed a decreased expression down to 15% and 3% respectively. These results suggest that by disrupting the dynein motor the MAPK pathway is affected, and the active form of MAPK is decreased. We then wanted to know if the decreased levels of active MAPK were a result of a deficiency in total MAPK. To answer this question, we probed the germlines for total MAPK and found that the total MAPK levels did not decrease in any of the treatments that disrupted dynein motor function. This allows us to make the conclusion that the depletion of active MAPK in seen in the germline is not due to a loss of total MAPK. Further analysis must be done to fully understand whether this disruption of activated MAPK is dependent on the dynein motor or microtubule transport. Nevertheless, these findings show a potential new role of the dynein motor in the activation of the MAPK pathway, which was previously unheard of. Since the MAPK pathway is known to play roles in diseases like cancer, identifying new contributors to its activation is relevant to advancing our understanding of the disease.